Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÁßÁõ Àڱ󻸷Áõ ȯÀÚÀÇ Àڱ󻸷°ú Á¤»óÀÎ Àڱ󻸷¿¡¼­ uPA, uPAR mRNA ¹ßÇöÀÇ Â÷ÀÌ¿¡ °üÇÑ ¿¬±¸ mRNA Expression Differences of uPA, uPAR in Eutopic Endometrium of Advanced Stage Endometriosis Patients

´ëÇѺÒÀÓÇÐȸÁö 2006³â 33±Ç 4È£ p.229 ~ 236
Ç㼺Àº, ÀÌÁö¿µ, ÀÌ¿îÁ¤, ¹®Çý¼º, Á¤Çý¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
Ç㼺Àº ( Hur Sung-Eun ) 
°Ç¾ç´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

ÀÌÁö¿µ ( Lee Ji-Young ) 
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
ÀÌ¿îÁ¤ ( Lee Woon-Jung ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
¹®Çý¼º ( Moon Hye-Sung ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
Á¤Çý¿ø ( Chung Hye-Won ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

Abstract

¸ñ Àû: Àڱ󻸷Áõ¿¡¼­ ±× º´Å»ý¸®¸¦ ¿¬±¸ÇÔ¿¡ À־ fibrinolytic system°úÀÇ ¿¬°ü¼ºÀ» ¾Ë¾Æº¸±â À§Çؼ­ Àڱ󻸷Áõ ȯÀÚ¿Í Àڱ󻸷ÁõÀÌ ¾Æ´Ñ ´ëÁ¶±ºÀÇ Àڱ󻸷¿¡¼­ urokinase plasminogenactivator (u-PA)¿Í urokinase type plasminogen activator receptor (u-PAR)ÀÇ mRNAÀÇ ¹ßÇöÀÇ Â÷À̸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

¿¬±¸¹æ¹ý: º»¿ø »êºÎÀΰú¸¦ ¹æ¹®ÇÑ Çѱ¹ÀÎ ¿©¼º Áß ¼ö¼úÀ» ÅëÇØ Àڱ󻸷ÁõÀ» Áø´Ü ¹ÞÀº 33¸íÀÇ È¯ÀÚ¿Í ³­¼Ò ³¶Á¾ µîÀÇ ¾ç¼º ÁúȯÀ¸·Î °³º¹¼úÀ̳ª °ñ¹Ý°æ ¼ö¼úÀ» ½ÃÇàÇÑ È¯ÀÚ Áß Àڱ󻸷ÁõÀÌ ¾øÀ½À» È®ÀÎÇÑ ¿©¼º 32¸íÀ» ´ëÁ¶±ºÀ¸·Î ÇÏ¿´´Ù. °¢°¢ÀÇ ´ë»óÀ¸·ÎºÎÅÍ ¾òÀº Àڱ󻸷 Á¶Á÷¿¡¼­ RNA¸¦ ÃßÃâÇÏ¿© RT-QC PCRÀ» ½ÃÇàÇÏ¿© ¾ò°íÀÚ ÇÏ´Â ´ë»óÀÇ mRNA ¾çÀ» Á¤·®È­ÇÏ¿© µÎ ±º °£¿¡ Â÷ÀÌ°¡ ÀÖ´ÂÁö¸¦ »ý¸®Áֱ⿡ µû¶ó ºñ±³ÇÏ¿´´Ù.

°á °ú: u-PA¿Í u-PARÀÇ mRNA´Â Àڱ󻸷Áõ ȯÀÚ ¹× ´ëÁ¶±º¿¡¼­ ¸ðµÎ ¹ßÇöÇÏ¿´À¸¸ç, Àڱ󻸷Áõ ȯÀÚ¿¡¼­ÀÇ u-PA mRNA´Â Áõ½Ä±â Àڱ󻸷¿¡¼­ ´ëÁ¶±º¿¡ ºñÇØ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³ô°Ô ¹ßÇöµÊÀ» °üÂûÇÏ¿´´Ù. u-PAR mRNA´Â µÎ ±º »çÀÌ¿¡¼­ »ý¸®ÁÖ±â Àü¹Ý¿¡ °ÉÃÄ ºñ±³ÇßÀ» ¶§ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù.

°á ·Ð: Àڱ󻸷ÁõÀÇ º´Å»ý¸®¿Í °ü·ÃÇÏ¿© u-PA¿Í u-PARÀÇ mRNA ¹ßÇö¿¡ ´ëÇؼ­ Á¶»çÇÑ °á°ú, u-PA mRNA°¡ Àڱ󻸷Áõ ȯÀÚ¿¡¼­ ´ëÁ¶±ºº¸´Ù Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³ô°Ô ¹ßÇöµÇ¾ú°í ÀÌ°ÍÀº Àڱ󻸷Áõ ȯÀÚÀÇ Àڱ󻸷ÀÇ ¼º°ÝÀÌ Á» ´õ ħ½ÀÀûÀÌ°í, ÀÌ·Î½á º¹¸·¿¡ÀÇ Ä§½À¿¡µµ ´õ À¯¸®ÇÑ ¿ªÇÒÀ» °¡Áø´Ù°í º¼ ¼ö ÀÖ´Ù. Àڱ󻸷Áõ¿¡ ´ëÇÑ ±âº»ÀûÀÎ º´Å»ý¸®·Î º¼ ¶§, Àڱ󻸷ÀÚü°¡ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» Çϸ®¶ó°í º¸¸ç, À̸¦ ´Ü¹éÁú ºÐÇØ´É°ú ¿¬°üÁö¾î »ý°¢ÇØ º¼ ¶§, u-PA ¹ßÇöÀÇ dysregulationÀÌ Àڱ󻸷ÀÇ Ä§½À¿¡ Áß¿äÇÑ º´Å»ý¸®¶ó°í »ý°¢µÈ´Ù.

Objective: We investigated the expression of uPA and uPAR in eutopic endometrium of advanced stage endometriosis and control patients.

Methods: The 33 endometriosis patients and 32 controls were enrolled. Endometrial samples were obtained from 65 premenopausal women aged 29~44 years, undergoing laparoscopic surgery or hysterectomy for non-malignant lesions. Sufficient samples were collected from 33 patients with endometriosis stage III and IV and 32 controls without endometriosis confirmed by laparoscopic surgery. The mRNA expression of uPA and uPAR from eutopic endometrium were analyzed by RT-QC PCR.

Results: The mRNAs of uPA and uPAR were expressed in eutopic endometrium from endometriosis and normal controls throughout the menstrual cycle. Uterine endometrium from women with endometriosis expresses significantly (p<0.05) higher levels of u-PA mRNA than endometrium from normal women without endometriosis in the proliferative phase. There were no significant differences in expression of uPAR in eutopic endometrium between controls and endometriosis patients.

Conclusion: These results suggest that eutopic endometrium from endometriosis patients may be more invasive and prone to peritoneal implantation because of greater u-PA mRNA expression than endometrium from women without endometriosis. Thus, increased proteolytic activity may be one etiology for the invasive properties of the endometrium resulting in the development of endometriosis.

Å°¿öµå

uPA; uPAR; Endometriosis; Proteolysis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS